IRIX News and Press, IRIDEX Corporation From 10/27/22

MOUNTAIN VIEW, Calif., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced the Company will release financial results for the third quar...

MicroPulse ® Transscleral Laser Therapy (TLT), continuous-wave transscleral cyclophotocoagulation (CW-TSCPC), and MicroPulse Laser Trabeculoplasty (MLT) are non-incisional treatments that expand ways to manage, preserve, and prolong vision for glaucoma patients. ...

Stifel research has downgraded its rating on eye-laser procedures company Iridex ( NASDAQ: IRIX ) to hold from buy, citing limited potential volume upside in H2 for the firm's Cyclo G6 platform to treat glaucoma. Shares of the micro-cap company fell 7% to $2.65 in Friday...

IRIDEX Corporation (IRIX) Q2 2022 Earnings Conference Call August 15, 2022 5:00 PM ET Company Participants Leigh Salvo - Investor Relations David Bruce - Chief Executive Officer Fuad Ahmad - Interim Chief Financial Officer Conference Call Participants ...

IRIDEX press release ( NASDAQ: IRIX ): Q2 GAAP EPS of -$0.14. Revenue of $13.8M (+3.0% Y/Y). Cyclo G6 product family revenue of $3.5 million, a decrease of 3% year-over-year 15,000 Cyclo G6 probes sold, a 6% decrease year-over-year and a 2% increase quarter-over-qu...

MOUNTAIN VIEW, Calif., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX) today reported financial results for the second quarter ended July 2, 2022. Second Quarter 2022 Highlights Total revenue of $13.8 million, an increase of 2% over the prior year period ...

MOUNTAIN VIEW, Calif., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced the Company will release financial results for the second qua...

Iridex (NASDAQ:IRIX) on Tuesday said it had got Chinese regulatory clearance to market and sell its Cyclo G6 platform for the treatment of glaucoma diseases. IRIX and its distribution distribution partners Topcon and Clinico will launch the Cyclo G6 system and related probes in Chin...

MOUNTAIN VIEW, Calif., June 14, 2022 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced that it has received regulatory clearance to market and sell its C...

IRIDEX Corporation (IRIX) Q1 2022 Earnings Conference Call May 12, 2022 5:00 PM ET Company Participants David Bruce – Chief Executive Officer Hunter Cabi – Investor Relations Fuad Ahmad – Interim Chief Financial Officer Conference Call Participants Tom Stephan – St...